Division of Endocrinology and Metabolic Bone Diseases, Diabetes and Bone Diseases, Department of Medicine III, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
Center for Healthy Ageing, Department of Medicine III, TU Dresden, Dresden, Germany.
J Cancer Res Clin Oncol. 2021 Aug;147(8):2233-2238. doi: 10.1007/s00432-021-03635-1. Epub 2021 Apr 21.
Neuropilin-1 (NRP-1) is a transmembrane protein that acts as a multifunctional non-tyrosine kinase receptor with an established role in development and immunity. NRP-1 also regulates tumor biology, and high expression levels of tissue NRP-1 have been associated with a poor prognosis. Recently, ELISA-based quantification of soluble NRP-1 (sNRP-1) has become available, but little is known about the prognostic value of sNRP-1 in malignancies.
We measured sNRP-1 in the serum of 509 patients with primary early breast cancer (BC) at the time of diagnosis using ELISA.
Mean serum values of sNRP-1 were 1.88 ± 0.52 nmol/l (= 130.83 ± 36.24 ng/ml). SNRP-1 levels weakly correlated with age, and were higher in peri- and postmenopausal patients compared to premenopausal patients, respectively (p < 0.0001). Low levels of sNRP-1 were associated with a significant survival benefit compared to high sNRP-1 levels at baseline (p = 0.005; HR 1.94; 95%CI 1.23-3.06). These findings remained significant after adjustment for tumor stage including lymph node involvement, grading, hormone receptor, HER2 status, and age (p = 0.022; HR 1.78; 95%CI 1.09-2.91).
Our findings warrant further investigations into the prognostic and therapeutic potential of sNRP-1 in BC.
神经纤毛蛋白-1（NRP-1）是一种跨膜蛋白，作为一种多功能非酪氨酸激酶受体，在发育和免疫中具有重要作用。NRP-1 还调节肿瘤生物学，组织 NRP-1 的高表达水平与预后不良相关。最近，基于 ELISA 的可溶性 NRP-1（sNRP-1）定量已成为可能，但关于 sNRP-1 在恶性肿瘤中的预后价值知之甚少。
我们使用 ELISA 在诊断时测量了 509 例原发性早期乳腺癌（BC）患者的血清中 sNRP-1。
sNRP-1 的平均血清值为 1.88±0.52 nmol/l（=130.83±36.24 ng/ml）。sNRP-1 水平与年龄呈弱相关，绝经前、围绝经期和绝经后患者的 sNRP-1 水平分别较高（p<0.0001）。与基线时高 sNRP-1 水平相比，低水平的 sNRP-1 与显著的生存获益相关（p=0.005；HR 1.94；95%CI 1.23-3.06）。这些发现在调整包括淋巴结受累、分级、激素受体、HER2 状态和年龄在内的肿瘤分期后仍然显著（p=0.022；HR 1.78；95%CI 1.09-2.91）。
我们的研究结果表明，进一步研究 sNRP-1 在 BC 中的预后和治疗潜力是合理的。
